Search hospitals > Ontario > TORONTO

Novartis Investigative Site

Claim this profile
TORONTO, Ontario M5G 2M9
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Leukemia
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Myeloid Leukemia
222 reported clinical trials
0 medical researchers
Photo of Novartis Investigative Site in TORONTOPhoto of Novartis Investigative Site in TORONTOPhoto of Novartis Investigative Site in TORONTO

Summary

Novartis Investigative Site is a medical facility located in TORONTO, Ontario. This center is recognized for care of Cancer, Breast Cancer, Leukemia, Non-Small Cell Lung Cancer, Myeloid Leukemia and other specialties. Novartis Investigative Site is involved with conducting 222 clinical trials across 204 conditions. There are 0 research doctors associated with this hospital, such as .

Area of expertise

1Cancer
Global Leader
Novartis Investigative Site has run 23 trials for Cancer. Some of their research focus areas include:
Stage IV
PD-L1 positive
Stage III
2Breast Cancer
Global Leader
Novartis Investigative Site has run 22 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 negative

Top PIs

Clinical Trials running at Novartis Investigative Site

Multiple Sclerosis
Food Allergy
Diffuse Large B-Cell Lymphoma
Chronic Urticaria
Ovarian Cancer
Squamous Cell Carcinoma
Breast Cancer
Anal Cancer
Skin Cancer
Mesothelioma
Image of trial facility.

Ofatumumab

for Multiple Sclerosis

Recruiting2 awards Phase 3

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Novartis Investigative Site?
Novartis Investigative Site is a medical facility located in TORONTO, Ontario. This center is recognized for care of Cancer, Breast Cancer, Leukemia, Non-Small Cell Lung Cancer, Myeloid Leukemia and other specialties. Novartis Investigative Site is involved with conducting 222 clinical trials across 204 conditions. There are 0 research doctors associated with this hospital, such as .